AG

agilon health, inc.

AGLHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$5.93B
-2.1% YoY
Net Income
-$391.3M
-50.4% YoY
EBITDA
-$368.9M
-69.1% YoY
Free Cash Flow
-$145.7M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3 MACD Negative CrossoverHistogram -0.2714, negative momentum
Sep 2 MACD Negative CrossoverHistogram -0.1345, negative momentum
About agilon health, inc.

Part of the healthcare sector, agilon health, inc. (AGL) is listed under Medical Care Facilities. Valued at $1.49B, AGL is a small-cap name in its sector. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month.

Where AGL stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, AGL finished 42.13% above its 150-day moving average ($61.48) and 72.04% above its 200-day moving average ($50.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AGL overbought or oversold?

At the September 3, 2026 close, AGL's RSI(14) was 47.5, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.49B
Fwd P/E43.06
EPS$-15.23
Beta3.04
52W Change+181.0%
ROE-78.9%
Analysis

The balance sheet looks solid with $185.6M in cash comfortably exceeding the $33.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$145.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -78.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $2.39B (2022) to $5.93B (2025), reflecting a 148% increase over the period.

A beta of 3.04 means AGL is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence agilon health, inc.'s trajectory.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms